Home » Newsletters » BioWorld Science

BioWorld Science

May 10, 2006

View Archived Issues

AP-5346 shows different kinetics and preclinical activity than oxaliplatin

Update on lacosamide at American Pain Society

Use of alvimopan for the gastrointestinal adverse effects of opioids studied

Q1 highlights at Schering-Plough

Novartis makes positive start to year

BioProgress and Uluru to develop antiemetic product

ALGRX-3268 local analgesia effective in children

Phase II studies show reduced pain with ALGRX-4975 in lateral epicondylitis, neuroma

Update on the antiatherosclerotic effects of D-4F

Oral RSD-1235 shows no significant effect on QT interval in healthy volunteers

ACR-16 improves Huntington's disease symptoms in phase II study

Cytogen enters into Quadramet royalty buyout agreement with Berlex

Roche to acquire trimeric Apo A-I compound from Borean Pharma

Phase I/II trial studying Lovaxin C to treat cervical cancer

VQD-002 IND accepted by FDA

Tindamax completes phase III trial for bacterial vaginosis

Femara recommended for use in Scotland

Pfizer and Monogram Biosciences collaborate on HIV Co-Receptor Tropism Assay

Hana completes licensing of three targeted cancer compounds from Inex

Eisai plans phase I study for E-2012 for Alzheimer's disease

Silicon phthalocyanine Pc 4 safe in ongoing phase I study in skin conditions

SGN-30 induces responses in cutaneous anaplastic large cell lymphoma patients

New coagulation factor Xa inhibitors emerge from Bristol-Myers Squibb R&D

Recent Sankyo and Inotek patents describe new treatments for cardiovascular diseases

Bayer patent describes therapeutic agents for urinary incontinence

Canadian approval for Velcade in second-line approval for multiple myeloma

Xcytrin NDA to be filed by year-end

Lilly seeks approval of Cymbalta for generalized anxiety disorder

Plavix launched in Japan

Opticin may contribute to the antiangiogenic properties of the vitreous humor

New intraocular delivery system of antiproliferative agents reported

A novel multitargeted tyrosine kinase prodrug proves beneficial for CNV disorders

Novel neuroprotective strategies in glaucoma therapeutics - Part II

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...